COLL · Collegium Pharmaceutical, Inc
$28.23
+0.08 (+0.28%)
At close · Aug 14
Market Cap
$919.04M
Shares
32.56M
Collegium Pharmaceutical, Inc Earnings Call Transcripts
Every quarterly earnings call for Collegium Pharmaceutical, Inc (COLL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲61.1%
$127.01M
$457,000
'22 Q3
22-11-03
▲373.7%
$129.62M
−$7.20M
'22 Q4
23-02-23
▲72.9%
$144.77M
−$17.43M
'23 Q1
23-05-04
▲9.7%
$135.55M
$13.01M
'23 Q2
23-08-03
▲7.6%
$136.71M
$20.63M
'23 Q3
23-11-07
▲15.5%
$149.75M
$31.94M
'23 Q4
24-02-22
▲0.1%
$144.92M
$27.71M
'24 Q1
24-05-09
▲7.2%
$145.28M
$19.61M
'24 Q2
24-08-08
▲16.5%
$159.30M
$9.34M
'24 Q3
24-11-07
▲21.5%
$181.95M
$12.54M
'24 Q4
25-02-27
▲22.7%
$177.76M
$2.42M
'25 Q1
25-05-08
▲29.4%
$188.00M
$11.98M
'25 Q2
25-08-07
▲31.4%
$209.36M
$31.51M
'25 Q3
25-11-06
▲12.9%
$205.45M
$16.96M
'25 Q4
26-02-26
▲8.9%
$193.52M
$14.50M
'26 Q1
26-05-07
LATEST
▲6.3%
$199.88M
−$15.05M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Q2 2026 Collegium Pharmaceutical, Inc. Earnings Conference Call
Confident tone
Astaris acquisition and integration
ADHD growth (Jornay PM)
Pain portfolio performance
Revenue
$199.88M
▲ 6.3% YoY Diluted EPS
$-0.46
▼ 235.3% YoY Gross margin
55.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Collegium Pharmaceutical, Inc Q1 FY2026 Earnings Call
Confident tone
AZSTARYS Acquisition
Pain Portfolio Durability
ADHD Sales Force & Market Coverage
Revenue
$193.52M
▲ 8.9% YoY Diluted EPS
$0.40
▲ 471.4% YoY Gross margin
60.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-15
25th Annual Needham Virtual Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-19
Collegium Pharmaceutical Investor Conference Call
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-26
Collegium Pharmaceutical, Inc Q4 FY2025 Earnings Call
Confident tone
Pain portfolio durability
Jornay PM growth
Capital deployment / business development
Revenue
$205.45M
▲ 12.9% YoY Diluted EPS
$0.46
▲ 27.8% YoY Gross margin
62.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Collegium Pharmaceutical, Inc Q3 FY2025 Earnings Call
Confident tone
Jornay PM Growth
Pain Portfolio Performance
Gross-to-Net & Inventory Dynamics
Revenue
$209.36M
▲ 31.4% YoY Diluted EPS
$0.84
▲ 211.1% YoY Gross margin
61.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Collegium Pharmaceutical, Inc Q2 FY2025 Earnings Call
Confident tone
Jornay PM Growth
Jornay Awareness / Marketing
Pain Portfolio Durability / Generic Defense
Revenue
$188.00M
▲ 29.4% YoY Diluted EPS
$0.34
▼ 34.6% YoY Gross margin
57.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Collegium Pharmaceutical, Inc Q1 FY2025 Earnings Call
Confident tone
Jornay PM Growth
Pain Portfolio Durability
Sales Force Expansion
Revenue
$177.76M
▲ 22.7% YoY Diluted EPS
$0.07
▼ 90.1% YoY Gross margin
54.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Collegium Pharmaceutical, Inc Q4 FY2024 Earnings Call
Confident tone
Jornay PM growth and ADHD franchise
Pain portfolio (BELBUCA, Xtampza ER, Nucynta)
Sales force expansion for Jornay
Revenue
$181.95M
▲ 21.5% YoY Diluted EPS
$0.36
▼ 56.1% YoY Gross margin
54.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Collegium Pharmaceutical, Inc Q3 FY2024 Earnings Call
Confident tone
ADHD market growth opportunity
Pain portfolio performance
Business development pipeline
Revenue
$159.30M
▲ 16.5% YoY Diluted EPS
$0.27
▼ 49.1% YoY Gross margin
60.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Collegium Pharmaceutical, Inc Q2 FY2024 Earnings Call
Confident tone
Ironshore Acquisition / Jornay PM
Pain Portfolio Performance
Financial Results
Revenue
$145.28M
▲ 7.2% YoY Diluted EPS
$0.52
▲ 52.9% YoY Gross margin
62.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Collegium Pharmaceutical, Inc Q1 FY2024 Earnings Call
Confident tone
Xtampza ER Performance
Belbuca Growth
Nucynta Franchise Outlook
Revenue
$144.92M
▲ 0.1% YoY Diluted EPS
$0.71
Gross margin
63.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Collegium Pharmaceutical, Inc Q4 FY2023 Earnings Call
Confident tone
Xtampza ER contract renegotiations
BELBUCA growth and outlook
Nucynta exclusivity extension
Revenue
$149.75M
▲ 15.5% YoY Diluted EPS
$0.82
Gross margin
63.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Collegium Pharmaceutical, Inc Q3 FY2023 Earnings Call
Revenue
$136.71M
▲ 7.6% YoY Diluted EPS
$0.53
▲ 5200% YoY Gross margin
58.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Collegium Pharmaceutical, Inc Q2 FY2023 Earnings Call
Revenue
$135.55M
▲ 9.7% YoY Diluted EPS
$0.34
Gross margin
54.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Collegium Pharmaceutical, Inc Q1 FY2023 Earnings Call
Revenue
$144.77M
▲ 72.9% YoY Diluted EPS
$-0.51
Gross margin
53.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Collegium Pharmaceutical, Inc Q4 FY2022 Earnings Call
Revenue
$129.62M
▲ 373.7% YoY Diluted EPS
$-0.21
Gross margin
38.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Collegium Pharmaceutical, Inc Q3 FY2022 Earnings Call
Revenue
$127.01M
▲ 61.1% YoY Diluted EPS
$0.01
▼ 95.5% YoY Gross margin
46.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Collegium Pharmaceutical, Inc Q2 FY2022 Earnings Call
Revenue
$123.55M
▲ 49% YoY Diluted EPS
$-0.15
▼ 108.4% YoY Gross margin
42.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Collegium Pharmaceutical, Inc Q1 FY2022 Earnings Call
Revenue
$83.75M
▼ 4.5% YoY Diluted EPS
$-0.39
▼ 195.1% YoY Gross margin
57.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Collegium Pharmaceutical, Inc Q4 FY2021 Earnings Call
Revenue
$27.36M
▼ 64.1% YoY Diluted EPS
$-0.73
▼ 465% YoY Gross margin
-4.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Collegium Pharmaceutical, Inc Q3 FY2021 Earnings Call
Revenue
$78.84M
▼ 0.4% YoY Diluted EPS
$0.22
▼ 31.2% YoY Gross margin
58.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Collegium Pharmaceutical, Inc Q2 FY2021 Earnings Call
Revenue
$82.94M
▲ 6.3% YoY Diluted EPS
$1.79
▲ 678.3% YoY Gross margin
60.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Collegium Pharmaceutical, Inc Q1 FY2021 Earnings Call
Revenue
$87.72M
▲ 14.7% YoY Diluted EPS
$0.41
▲ 4000% YoY Gross margin
63.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Collegium Pharmaceutical, Inc Q4 FY2020 Earnings Call
Revenue
$76.27M
▲ 2.8% YoY Diluted EPS
$0.20
Gross margin
58.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Collegium Pharmaceutical, Inc Q3 FY2020 Earnings Call
Revenue
$79.18M
▲ 8.5% YoY Diluted EPS
$0.32
Gross margin
60.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Collegium Pharmaceutical, Inc Q2 FY2020 Earnings Call
Revenue
$78.06M
▲ 4% YoY Diluted EPS
$0.23
Gross margin
62.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Collegium Pharmaceutical, Inc Q1 FY2020 Earnings Call
Revenue
$76.51M
▲ 2.7% YoY Diluted EPS
$0.01
Gross margin
51.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Collegium Pharmaceutical, Inc Q4 FY2019 Earnings Call
Revenue
$74.20M
▲ 1.1% YoY Gross margin
33.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–30 of 30 earnings calls
Key facts
CIK
1267565
CUSIP
19459J104
13F (30d)
270 filings
264 filers
Visit website
Investor relations